CAJ | 학술논문

目的：评价术前多西他赛＋顺铂（DP）与吉西他滨＋顺铂方案（GP）辅助化疗治疗Ⅲa 期中央型非小细胞肺癌（NSCLC）的临床疗效及安全性。方法我科收治Ⅲa 期中央型 NSCLC 患者58例随机分为 DP 组27例和 GP 组31例。 DP组第1天静脉滴注多西他赛75 mg? m-2，顺铂75 mg? m-2，21 d 为1周期；GP组第1，8天静脉滴注吉西他滨1000 mg ? m-2，第1天静脉滴注顺铂70 mg? m-2，28 d 一个周期。2组患者术前共辅助化疗2～3周期。评价2组客观有效率（ORR）。结果DP 组和 GP 组 ORR 分别为44．4％（12/27）和38．7％（12/31），手术切除率（RR）分别为66．7％（18/27）和54．8％（17/31），2组差别均无统计学意义（P ＞0．05）。 DP 组与 GP 组Ⅲ/Ⅳ血液学毒性发生率分别为11．1％（3/27）和29．0％（9/31），DP 组显著低于 GP 组（P ＜0．05）。结论DP 与 GP 新辅助治疗Ⅲa 期中央型 NSLCL 的临床疗效无明显差别，但 DP 方案血液学毒性较低。
목적：평개술전다서타새＋순박（DP）여길서타빈＋순박방안（GP）보조화료치료Ⅲa 기중앙형비소세포폐암（NSCLC）적림상료효급안전성。방법아과수치Ⅲa 기중앙형 NSCLC 환자58례수궤분위 DP 조27례화 GP 조31례。 DP조제1천정맥적주다서타새75 mg? m-2，순박75 mg? m-2，21 d 위1주기；GP조제1，8천정맥적주길서타빈1000 mg ? m-2，제1천정맥적주순박70 mg? m-2，28 d 일개주기。2조환자술전공보조화료2～3주기。평개2조객관유효솔（ORR）。결과DP 조화 GP 조 ORR 분별위44．4％（12/27）화38．7％（12/31），수술절제솔（RR）분별위66．7％（18/27）화54．8％（17/31），2조차별균무통계학의의（P ＞0．05）。 DP 조여 GP 조Ⅲ/Ⅳ혈액학독성발생솔분별위11．1％（3/27）화29．0％（9/31），DP 조현저저우 GP 조（P ＜0．05）。결론DP 여 GP 신보조치료Ⅲa 기중앙형 NSLCL 적림상료효무명현차별，단 DP 방안혈액학독성교저。
Objective To evaluate the efficacy and safety of DP vs GP regimen with preoperative adjuvant chemotherapy on central stage Ⅲ a non -small cell lung cancer (NSCLC).Methods Fifty -eight cases of central stage Ⅲ a NSCLC patients were recruited in this prospective study.All the cases were randomly divided into DP group (n =27) and GP group (n =31).Patients in DP group were treated with 75 mg? m-2 of docetaxel and cisplatin on the first day , 21 days as a cycle.And cases in the GP group received 1000 mg? m 2 of gemcitabine on the first and eighth day as well as 70 mg? m-2 of cisplatin by intravenous infusion on day one, 28 days as a cycle.Patients in both groups received 2 -3 cy-cles adjuvant chemotherapy.Results The objective response rate and operative rate in DP and GP were 44.4% (12 /27)vs 38.7%(12 /31) and 66.7%(18 /27)vs 54.8%(17 /31)respectively, which demonstrated no statistical difference between the two groups were observed .The Ⅲ/Ⅳ hematologic toxicity were 11.1%(3 /27) and 29.0%(9 /31) in DP and GP regimen respectively, which showed it was much higher in GP regimen ( P <0.05) .Conclusion There was no significant clinical efficacy in the DP and GP chemotherapy regimens for the treatment of central stage Ⅲa NSCLC, but there is a lower risk of developing Ⅲ/Ⅳhematologic toxicity in DP regimen.